Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.
Under the deal, Cenix will use its high-throughput screening and high-content assay know-how to identify predictive biomarkers for Debiopharm’s preclinical oncology candidates.
“Multi-parametric microscopy-based readouts established by Cenix … will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug's therapeutic effects,” the company said.
Specific terms of the arrangement were not disclosed.